Trial Profile
A Phase 1b, Open-label, Single-arm, Dose-selection, Proof-of-concept Study to Assess the Safety and Efficacy of a Novel HSP90 Inhibitor (CUDC-305) in the Treatment of Moderate to Severe Plaque Psoriasis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 13 Apr 2023
Price :
$35
*
At a glance
- Drugs RGRN-305 (Primary)
- Indications Plaque psoriasis
- Focus Proof of concept; Therapeutic Use
- 09 Jul 2019 Status changed from not yet recruiting to recruiting.
- 22 Sep 2018 New trial record